Questions

826. Deputy Jennifer Whitmore asked the Minister for Health the number of women waiting to be reimbursed under the Cross Border Directive after having availed of the scheme for endometriosis treatment; and if she will make a statement on the matter. [53165/26]

827. Deputy Jennifer Whitmore asked the Minister for Health if endometriosis treatment is included in the treatment abroad scheme; if not, the reason; and if she will make a statement on the matter. [53166/26]

885. Deputy Pádraig O'Sullivan asked the Minister for Health the annual cost of the national unused medicines return and disposal scheme; the details of the contract awarded to the appointed waste disposal provider including its duration and value; whether the contract was subject to competitive tender; and if she will make a statement on the matter. [53451/26]

898. Deputy Erin McGreehan asked the Minister for Health her plans to consider GLP1 drugs to be included under the drugs payments scheme for persons prescribed it for medical conditions other than diabetes for example polycystic ovary syndrome (PCOS); and if she will make a statement on the matter. [53573/26]

453. Deputy Michael Healy-Rae asked the Minister for Health to review the case of a person (details supplied); her views on a compensation scheme for long-Covid patients; and if she will make a statement on the matter. [50441/26]

490. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 1276 of 26 May 2026 if the national treatment abroad office in Kilkenny is the sole point of approval for all treatment abroad scheme applications; and the circumstances under which an application is approved, reviewed, or processed outside the Kilkenny office. [50561/26]

491. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 1276 of 26 May 2026 to confirm whether the HSE maintains a written procedure, circular, or delegated authority schedule setting out which staff grade or management level is authorised to approve treatment abroad scheme applications; and if no such written procedure exists, the basis on which approval authority is exercised. [5…

492. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 267 of 27 May 2026 to provide a response concerning whether an approval rate benchmarking exists between specialties, consultants, or regions under the treatment abroad scheme, noting that the previous response addressed an unrelated question on the age profile of overseas gender affirmation surgery approvals rather than the q…

502. Deputy Ken O'Flynn asked the Minister for Health to provide the specific euro threshold or thresholds above which Grade VII approval no longer applies to treatment abroad scheme applications; the grade or officeholder responsible for authorising applications above each such threshold; and the nature of the "applicable derogations" referenced in the Health Service Executive's reply of 19th June 2026. [50582/26]

505. Deputy Ken O'Flynn asked the Minister for Health given that individual figures may be withheld on confidentiality grounds, to provide the highest individual expenditure approved under the treatment abroad scheme in each year since 2020 in banded form (for example, within ranges of €50,000); and to confirm whether any approved application since 2020 exceeded €500,000. [50585/26]

506. Deputy Ken O'Flynn asked the Minister for Health to confirm directly whether the Comptroller and Auditor General has examined the treatment abroad scheme specifically at any point since 2020; to provide the date of any such examination; and to confirm whether any external, non-HSE body has conducted a value-for-money or governance review of the scheme since 2020. [50586/26]

507. Deputy Ken O'Flynn asked the Minister for Health to confirm directly whether the absence of publicly available approval thresholds within the treatment abroad scheme appears on the Health Service Executive's corporate risk register; and if it does not, to confirm this directly rather than by general reference to oversight arrangements. [50587/26]

508. Deputy Ken O'Flynn asked the Minister for Health further Parliamentary Question No. 581 of 14 June 2026, in which the Health Service Executive did not address the substantive matter raised, to confirm whether the treatment abroad scheme dataset records the age of patients approved for funding of overseas gender affirmation surgeries; if this data is not currently captured, to state the reason; and if her Departm…

509. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 1116 of 19 May 2026, in which expenditure figures were provided for treatment costs and travel costs only, to confirm whether the figures published include accommodation, administration, translation, or assessment costs; if so, to provide a separate costed breakdown of each category for the years 2020 to 2025; the way in which…

818. Deputy William Aird asked the Minister for Health when a new vehicle adaptation scheme will be put in place; and if she will make a statement on the matter. [49108/26]

901. Deputy Conor Sheehan asked the Minister for Health for an update on the exceptional patient scheme or discretionary funding for GLP-1 medications for severe, treatment-resistant metabolic disorders, including polycystic ovary syndrome, PCOS, where insulin resistance cannot be managed by metformin; and if she will make a statement on the matter. [49594/26]

515. Deputy David Cullinane asked the Minister for Health the estimated cost of making the contraception scheme universal in scope. [48664/26]

516. Deputy David Cullinane asked the Minister for Health the estimated cost of doubling and trebling entitlements under public access to IVF. [48665/26]

1912. Deputy Ryan O'Meara asked the Minister for Health the efforts being made to expand the eligibility criteria for publicly funded AHR treatment to provide more equitable access; if the inclusion of DAHR is currently under review; if so, the current status of the matter with her Department; and if she will make a statement on the matter. [41879/26]

2058. Deputy Ken O'Flynn asked the Minister for Health whether the absence of any national clinical audit relating to procedures funded under the Treatment Abroad Scheme since 2020 is considered acceptable from a patient-safety and governance perspective; and if she will make a statement on the matter. [42505/26]

2059. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has conducted any risk assessment regarding the absence of national clinical outcome auditing for procedures funded under the treatment abroad scheme; and if she will make a statement on the matter. [42506/26]

2060. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any mechanism to systematically monitor complication rates, revision procedures, adverse outcomes, readmissions, or long-term follow-up care requirements arising from procedures funded under the Treatment Abroad Scheme; and if she will make a statement on the matter. [42507/26]

2061. Deputy Ken O'Flynn asked the Minister for Health whether any national framework exists governing post-treatment outcome monitoring for patients returning to Ireland following procedures funded under the Treatment Abroad Scheme; and if she will make a statement on the matter. [42508/26]

2062. Deputy Ken O'Flynn asked the Minister for Health whether the HSE National Centre for Clinical Audit has ever been requested by her Department, the HSE, or the Treatment Abroad Scheme to consider conducting a national clinical audit relating to procedures funded under the Treatment Abroad Scheme; and if she will make a statement on the matter. [42509/26]

2063. Deputy Ken O'Flynn asked the Minister for Health whether any official within her Department or the HSE holds responsibility for assessing whether procedures funded under the Treatment Abroad Scheme should be subject to national clinical audit or outcome monitoring; and if she will make a statement on the matter. [42510/26]